Rocket


Overview
Financials
News + Filings
Key Docs
Ownership


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Affimed N.V. (AFMD) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/04/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Affimed Announces Listing Transfer to NASDAQ Capital Markets Mannheim, Germany, October 4, 2023 - Affimed N.V. , a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it has received approval from the Listing Qualifications Department of the Nasdaq Stock Market to transfer the listing of its shares from the Nasdaq Global Market to the Nasdaq Capital Market. This transfer is effective as of the opening of business on October 4, 2023. This announcement has no immediate effect on the listing or trading of the Company's common shares. The Company's shares will continue to trade under the “AFMD” ticker symbol. The approval by Nasdaq was conditioned upon the Company meeting the applicable market value requirement of ..."
08/10/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"TOTAL EQUITY AND LIABILITIES",
"S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF",
"ex vivo"
07/07/2023 SC 13G/A BlackRock Inc. reports a 0.8% stake in AFFIMED N.V.
05/23/2023 6-K Quarterly results
Docs: "6-K",
"Affimed N.V. Unaudited Condensed Consolidated Interim Financial Statements as of March 31, 2023",
"Affimed N.V. Management's Discussion and Analysis of Financial Condition and Results of Operations",
"Affimed Reports First Quarter 2023 Financial Results and Highlights Operational Progress",
"Affimed Announces IND Clearance for a Phase 2 Clinical Trial Investigating AFM13 and AB-101 Combination Therapy"
03/23/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/23/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
03/23/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Affimed Reports 2022 Financial Results and Operational Progress"
03/23/2023 20-F Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
02/14/2023 SC 13G/A Ridgeback Capital Investments L.P. reports a 8.8% stake in Affimed N.V.
02/14/2023 SC 13G/A Ridgeback Capital Investments L.P. reports a 8.8% stake in Affimed N.V.
02/14/2023 SC 13G/A Point72 Asset Management, L.P. reports a 2.8% stake in Affimed N.V.
02/14/2023 SC 13G/A 683 Capital Management, LLC reports a 6.2% stake in Affimed N.V.
02/03/2023 SC 13G BlackRock Inc. reports a 5.6% stake in AFFIMED N.V.
01/09/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Affimed Reports on Corporate Progress and Provides Regulatory Update for AFM13"
12/12/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Affimed Provides Updated Clinical Data from Phase 1/2 Study of AFM13 Precomplexed with Cord Blood-Derived NK Cells at the ASH 2022 Annual Meeting",
"Affimed Reports Topline Data from AFM13 Monotherapy Phase 2 REDIRECT Study in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma"
11/15/2022 6-K Quarterly results
11/03/2022 6-K Quarterly results
08/11/2022 6-K Quarterly results
06/23/2022 6-K Quarterly results
06/01/2022 6-K Quarterly results
05/24/2022 6-K Quarterly results
05/09/2022 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
04/21/2022 SC 13G Gilde Healthcare Holding B.V. reports a 5.6% stake in Affimed N.V.
04/18/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Underwriting Agreement, by and among Affimed N.V., Jefferies LLC, SVB Securities LLC, Truist Securities, Inc. and Wells Fargo Securities, LLC, as representatives of the underwriters",
"Opinion of De Brauw Blackstone Westbroek N.V. with respect to the Underwritten Shares",
"Opinion of De Brauw Blackstone Westbroek N.V. with respect to the Over-Allotment Shares"
04/14/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
04/12/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
04/11/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Affimed Presents Findings from the Dose-escalation Phase of the First-in-human Study of AFM24 in Patients with EGFR-positive Solid Tumors",
"Affimed Presents Updated Clinical Data from Phase 1/2 Study of AFM13 Precomplexed with Cord Blood-Derived NK Cells at AACR Annual Meeting"
04/07/2022 EFFECT Form EFFECT - Notice of Effectiveness:
03/31/2022 POS AM Form POS AM - Post-Effective amendments for registration statement:
03/31/2022 20-F Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
03/31/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Affimed Reports 2021 Financial Results and Highlights Recent Operational Progress"
03/31/2022 POSASR Form POSASR - Post-effective Amendment to an automatic shelf registration statement:
02/14/2022 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/14/2022 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy